VanEck Junior Gold Miners vs Relay Therapeutics Inc. Common Stock — how do they compare? VanEck Junior Gold Miners trades at $114.09 (market cap $8.22B), while Relay Therapeutics Inc. Common Stock trades at $18.31 (market cap $3.82B). The key difference: VanEck Junior Gold Miners is far larger — about 2.2× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| GDXJ | RLAY | |
|---|---|---|
Market Cap | $8.22B | $3.82B |
Volume | 3,212,198 | 4,332,079 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $20.75 |
52-Week Low | $87.56 | $6.03 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $113.02, up 3.56% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies added in September 2026, potentially increasing diversification. Key support lies at $110, with resistance at $113. Financial ratios are not applicable as this is a fund tracking an index of gold mining equities.
The outlook remains cautious due to bearish technicals, though inclusion of new holdings may attract flows. Risks include gold price volatility and mining sector operational challenges. Analyst views on constituent stocks vary, but the ETF offers exposure to small-cap gold miners, which can be high-risk, high-reward during gold rallies.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →